Rapport Therapeutics, Inc.
RAPP- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0002012593
In the last 90 days, Rapport Therapeutics, Inc. insiders filed 0 open-market purchases and 8 sales; 160 institutions reported holding it in 13F filings for Q2 2026, worth $2.13B in total; no superinvestor holds it.
Q3 2025 vs. Q2 2025
How the institutions holding Rapport Therapeutics, Inc. changed between Q2 2025 and Q3 2025.
All holders in Q3 2025All holders in Q2 2025
| Measure | Q2 2025 | Q3 2025 | Change |
|---|---|---|---|
| Holders | 82 | 124 | +42 |
| Shares | 38.5M | 49.3M | +10.8M (+28.0%) |
| Value | $437.9M | $1.46B | +$1.03B (+234.2%) |
New holders (51)
Institutions that held Rapport Therapeutics, Inc. at the end of Q3 2025 but not at the end of Q2 2025.
Sold out (9)
Institutions that held Rapport Therapeutics, Inc. at the end of Q2 2025 and filed for Q3 2025 without it.
| Institution | Shares, Q2 2025 | Value, Q2 2025 |
|---|---|---|
| Logos Global Management LP | 208,910 | $2.38M |
| Affinity Asset Advisors, LLC | 199,643 | $2.27M |
| Woodline Partners LP | 185,028 | $2.10M |
| Driehaus Capital Management LLC | 131,340 | $1.49M |
| Deep Track Capital, LP | 98,237 | $1.12M |
| Acuta Capital Partners, LLC | 20,000 | $227.4K |
| Intech Investment Management LLC | 11,462 | $130.3K |
| Kennedy Capital Management, Inc. | 11,230 | $127.7K |
| Parallel Advisors, LLC | 50 | $569 |